Alicia Gallegos wrote a great article about GLP-1 semaglutides and studies that are finding muscle mass loss as a side effect.
The rise of GLP-1 agonists has revolutionized obesity treatment, achieving weight loss results previously only possible through surgery, but this breakthrough comes with unexpected challenges.
Medical professionals are now observing that patients using these medications are experiencing significant muscle mass loss, with studies showing that 25-39% of total weight lost over 36-72 weeks comes from fat-free mass.
As healthcare providers grapple with this emerging concern, obesity specialists are emphasizing the critical importance of early intervention through increased protein intake and physical activity to preserve muscle mass during GLP-1-assisted weight loss.
For more detail on the studies done and the statistics, please visit the link below.
コメント